An interventional study of spastic hand sugery and Botulinum Toxin A in Stroke, sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-30.
Sponsored by Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 323 studies in Stroke with a site in Spain — 73 open to participants now, 91 under way, 6 of them phase 3. Stroke · Spain.
Among the 323 studies in Stroke with a site in Spain, this one is the 158th largest by planned enrollment of the 246 interventional ones that give a count, is one of 22 that started in 2021, is one of 159 with no phase, reaches primary completion later than 9 of the 90 other live ones, and was the 262nd registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →73 of the 323 studies in Stroke with a site in Spain are open now. Recruiting first, the newest first:
Neuron, Spain · Sites in Spain
Ages 18+ · Healthy volunteers
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18–80
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain, Belgium, Germany and 3 more countries
Ages 18+
Ancor Rebassa Cabrera · Sites in Spain
Ages 18+
Dr. Yaroslav Winter · Sites in Spain, Czechia, Germany and 1 more country
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
323 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 21 · Phase 3 44 · Phase 4 21
First in 1998; this study’s year is marked. 22 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is close to the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 70 across the 246 interventional studies, 250 across the 77 observational. Of the 197 that completed or were terminated, 33 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 323 have an industry lead sponsor. The 10 most frequent:
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
24 of the studies in Stroke with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT06296082Phase 3Universiteit AntwerpenComparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity | 2026-12-30 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07497464Alfredo Lerín CalvoValidity of an Open-access Handedness Recognition Task in Stroke Patients | 2026-11 |
Add all 24 to your calendar (.ics) → With an account.
Among the 323 studies in Stroke with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
We present a research project in the form of a controlled clinical trial with the aim of analyzing and demonstrating whether the surgical treatment of upper limb spasticity is an effective and efficient measure to improve dependence and quality of life perceived by patients with sequelae of stroke and therefore, should be included in the therapeutic protocols, in which it is not usually contemplated, as a complement or alternative to traditional treatment with botulinum toxin, rehabilitation and occupational therapy.
Cerebrovascular accident (CVA) or "stroke" is the leading cause of permanent disability in adulthood and many patients require lifelong medical treatment and assistance from other people for the development of their daily activities. The repercussion in the family, professional, labor and social fields is enormous, producing a very important economic expense. The usual treatment of spastic upper limb secondary to stroke is rehabilitation, occupational therapy and periodic injection of botulinum toxin, and surgical correction is not usually considered. A two-arm Randomized Clinical Trial [surgical treatment (n=22) vs. botulinum toxin (n=22)] is proposed with the aim of investigating the efficacy and efficiency of surgery for upper limb spasticity with respect to treatment with botulinum toxin in patients with established spastic sequelae after stroke.
We will evaluate the effect on functionality and "hygienic" changes; the impact on quality of life, sleep quality, anxiety and depression; as well as on brain activity by Functional Magnetic Resonance Imaging, at baseline and at 6 and 12 months follow-up. The health and care costs of the established groups of patients will also be evaluated. This research is framed in the context of chronic diseases, aging and patients with functional and mobility difficulties. The results of this work are expected to have a great impact due to the high prevalence of the disease, the severe disability it causes, and the number of patients who would benefit, in addition to the savings in healthcare resources. The incorporation of surgery into stroke care would change the current treatment paradigm, favoring the formation of multidisciplinary teams for the treatment of the disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who meet the inclusion criteria and who will be treated with botulinum toxin (1 injection/4months).
Drug: Botulinum Toxin A
Patients who meet the inclusion criteria and who will be treated by surgery.
Procedure: spastic hand sugery
Deformity correction can be performed with single event multilevel surgery, using a combination of soft tissue releases and lengthening, tendon transfers and joint stabilization procedures. In addition, selective and supraselective neurectomies can also be performed.
Treatment consists of periodic injections of the toxin into the spastic muscles. It causes reversible chemical denervation by preventing the release of acetylcholine vesicles at the neuromuscular junctions of the affected muscles.
Quality of life by 36-Item Short Form Survey Instrument (SF-36)
SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and have been widely used.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Quality of life by Newcastle Stroke-Specific Quality of Life Measure
is a specific questionnaire to measure the QoL of patients who suffered a stroke. It was developed and validated by Buck et al. It is different from other questionnaires because it includes domains of vision, cognition and communication, and it can used for patients with ischaemic or haemorrhagic stroke and motor aphasia.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Functional outcome by Asworth scale
It measures the degree of spasticity from 0 to 5. Significant improvement of at least 1 of the 5 joints evaluated (elbow, forearm, wrist, thumb, fingers) will be considered a positive result.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Functional outcome by House hand function scale
Scale of hand function with 10 degrees of capability
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Functional outcome by Fugl-mayer scale
is the first quantitative evaluative instrument for measuring sensorimotor stroke recovery, based on Twitchell and Brunnstrom's concept of sequential stages of motor return in the hemiplegic stroke patient.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Functional outcome by GAS score
5-grade scale for the domains hygiene, esthetics and pain. Krasny-Pacini y cols, 2013
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Carer Burden by Carer Burden Score
Scores the caregiver's degree of difficulty for 4 basic activities (nail clipping, palm grooming, armpit grooming, arm dressing) on a 5-point Likert scale.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Pain by Visual Analogue Scale
A tool used to help a person assess the intensity of certain sensations and feelings, such as pain. The visual analogue pain scale is a straight line where one end means no pain and the other end means the worst pain imaginable. The patient marks a point on the line that matches the amount of pain he or she feels.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Sleep health by SATED scale
5 questions scale about satisfaction, alertness, timing, efficiency and duration of sleep to know the sleep health of patients. Higher scores (0-10) mean better sleep health.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Anxiety and depression by HADS scale
Includes 14 items, with scores from 0 to 3 (higher scores reflect greater severity of symptomatology).
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Activity, structure and brain function by MRI
Functional Magnetic Resonance Imaging (fMRI) at rest and with the patient's repeated attempt to extend the elbow and wrist. Anatomical and functional volumes shall be obtained by MRI and fMRI imaging, using a Siemens Prisma 3T functional MRI.
Time frame: t0 (basal assesment) t1 (6 months evaluation) t2 (12 months evaluation)
Started Jan 2021 (actual). Primary completion is estimated for Jun 2024, 41 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 41 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental